<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2509222632
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESMERON 10MG\ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROCURONIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        215.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" N.V. Organon" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             N.V. Organon
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03AC09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class of drugs</p><p>Esmeron is a muscle relaxant. Muscle relaxants are used during an operation as part of general anaesthesia. During an operation, your muscles must be completely relaxed to make it easier for the surgeon to perform the operation. Normally the nerves send signals to the muscles. Esmeron can temporarily block these signals, causing the muscles to relax. Because the muscles needed for breathing also become relaxed, you will be on a ventilator until you can breathe on your own. During the operation the effect of the muscle relaxant will be monitored constantly and, if necessary, more Esmeron will be given. At the end of surgery, the effects of Esmeron are allowed to wear off until you start breathing on your own again. Sometimes another drug is given to help speed up this recovery.</p><p>Esmeron can also be used in the Intensive Care Unit.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not receive Esmeron</strong></p><p>&bull; <strong>if you are allergic </strong>(<em>hypersensitive</em>) to rocuronium, the bromide ion or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>&mdash;&gt; <strong>Tell your anaesthetist if this applies to you.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your anaesthetist before you receive this medicine:</p><p>&bull; if you are allergic to <strong>muscle</strong><strong> relaxants</strong></p><p>&bull; if you have had <strong>kidney, heart</strong>, <strong>liver </strong>or <strong>gall bladder</strong><strong> </strong>disease</p><p>&bull; if you have had diseases affecting <strong>nerves </strong>and <strong>muscles</strong></p><p>&bull; if you have <strong>fluid retention</strong><strong> </strong>(<em>oedema</em>).</p><p>&mdash;&gt; <strong>Tell your anaesthetist if any of these applies to you.</strong></p><p>&bull; if you have a history of malignant hyperthermia (sudden fever with rapid heartbeat, rapid breathing and stiffness, pain and/or weakness in your muscles)</p><p><strong>&nbsp;</strong></p><p><strong>Some conditions may influence the effects of Esmeron &mdash; for example:</strong></p><p>&bull; low calcium levels in the blood</p><p>&bull; low potassium levels in the blood</p><p>&bull; high magnesium levels in the blood</p><p>&bull; low levels of protein in the blood</p><p>&bull; too much carbon dioxide in the blood</p><p>&bull; loss of too much water from the body, for example by being sick, diarrhoea or sweating</p><p>&bull; over-breathing leading to too little carbon dioxide in the blood (<em>alkalosis</em>)</p><p>&bull; general ill-health</p><p>&bull; burns</p><p>&bull; being very overweight (<em>obesity</em>)</p><p>&bull; very low body temperature (<em>hypothermia</em>).</p><p>&nbsp;</p><p>If you have any of these conditions, your anaesthetist will take it into account when deciding the correct dose of Esmeron for you.</p><p><strong>&nbsp;</strong></p><p><strong>Children and Elderly</strong></p><p>Esmeron can be used in children (newborns and adolescence) and elderly but your anaesthetist should first assess your medical history.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Esmeron</strong></p><p>&mdash;&gt; <strong>Tell your anaesthetist if you are taking other medicines </strong>or have recently taken them. This includes medicines or<strong> </strong>herbal products that you have bought without a prescription.<strong> &nbsp;</strong>Esmeron may affect other medicines or be affected by them.</p><p>&nbsp;</p><p><strong>Medicines which increase the effect of Esmeron:</strong></p><p>&bull; certain <strong>antibiotics</strong></p><p>&bull; certain medicines for <strong>heart disease </strong>or <strong>high blood pressure </strong>(<em>water tablets, calcium channel blockers, beta-blockers and</em><strong> </strong><em>quinidine</em>)</p><p>&bull; certain <strong>anti-inflammatory </strong>medicines (<em>corticosteroids</em>)</p><p>&bull; medicines for <strong>manic depressive illness </strong>(<em>bipolar</em><em> disorder</em>)</p><p>&bull; <strong>magnesium salts</strong></p><p>&bull; certain medicines used to treat <strong>malaria</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Medicines which decrease the effect of Esmeron:</strong></p><p>&bull; certain medicines for <strong>epilepsy</strong></p><p>&bull; <strong>calcium chloride </strong>and <strong>potassium chloride</strong></p><p>&bull; certain <strong>protease inhibitors </strong>called gabexate and ulinastatin.</p><p>&nbsp;</p><p>In addition, you may be given other medicines before or during surgery which can alter the effects of Esmeron. These include certain anaesthetics, other muscle relaxants, medicines such as phenytoin and medicines which reverse the effects of Esmeron.&nbsp; Esmeron may make certain anaesthetics work more quickly.&nbsp; Your anaesthetist will take this into account when deciding the correct dose of Esmeron for you.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast feeding</strong></p><p>&mdash;&gt;<strong>Tell your anaesthetist if you are pregnant or might be pregnant, or if you are breast feeding.</strong></p><p>Your anaesthetist may still give you Esmeron, but you need to discuss it first. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your anaesthetist or other doctor for advice before taking this medicine. Esmeron may be given to you if you are having a Caesarean section.</p><p>Breastfeeding should be suspended 6 hours after use of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines until advised it is safe to do so. Because Esmeron is given as part of a general anaesthetic, you may feel tired, weak or dizzy for some time afterwards. Your anaesthetist will be able to advise you on how long the effects are likely to last.</p><p>&nbsp;</p><p><strong>Esmeron contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dosage</p><p>The doctor will determine the dose of Esmeron, based on:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; what type of anaesthetic is used</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the expected duration of the surgery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; other medications you are taking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; your age and health status.</p><p>&nbsp;</p><p>You will be given Esmeron before and/or during a surgical procedure. The usual dose is 0.6 mg rocuronium bromide per kg body weight and the effect lasts 30 to 40 minutes. During the procedure it will be checked if Esmeron is still working. You may be given additional doses, if needed.</p><p>&nbsp;</p><p>How Esmeron is administered</p><p>Esmeron is not a drug you take yourself. Esmeron is a solution that is injected in a vein. It is administered as one single injection or as a continuous IV infusion.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt'><span style='mso-element:field-begin;mso-field-lock:
yes'></span>SHAPE<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span
style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:465.25pt;
 height:15.4pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' o:allowincell="f" filled="f"
 strokeweight=".82pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.7pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.35pt;margin-bottom:.0001pt;text-indent:0in;punctuation-wrap:
    simple;mso-line-break-override:restrictions'>The<span style='letter-spacing:
    -.1pt'> </span><span style='letter-spacing:-.05pt'>injections</span> <span
    style='letter-spacing:-.05pt'>must</span><span style='letter-spacing:.05pt'>
    </span>be<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:
    -.05pt'>given</span> by<span style='letter-spacing:-.15pt'> </span>a <span
    style='letter-spacing:-.05pt'>doctor</span><span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.1pt'>or</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>nurse.<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="625" height="25" alt="Text Box: The injections must be given by a doctor or nurse." src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:465.25pt;
 height:15.4pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Overdose</p><p>As medical personnel will be monitoring your condition carefully during the procedure, it is unlikely that you will be given too much Esmeron. However, if this should still happen, you will be kept on a ventilator until you are able to breathe again on your own. It is possible to counter the effects of (too much) Esmeron and speed up your recovery by giving you a drug that counteracts the effects of Esmeron.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anaesthesia, they will be noticed and treated by your doctor.</p><p>The following side effects can occur:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Common (in 1 to 10 out of 100 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate (tachycardia) in children (newborns to young adults)</p><p>&nbsp;</p><p>Uncommon/rare (in 10 to 100 out of 10,000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate (tachycardia) in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; no effect or a decreased or increased effect of Esmeron</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; pain at the site of injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; redness or itching at the site of injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; prolongation of the muscle-relaxing effect of Esmeron</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; delayed recovery from the anaesthesia.</p><p>&nbsp;</p><p>Very rare (in less than 1 out of 10,000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, such as difficulty breathing, changes in blood pressure or heart rate, shock (sharp decrease in blood pressure) as a consequence of too little circulating blood, or changes in the skin (such as fluid retention, redness or rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath due to cramping of the muscles in the airways (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; sudden fever with rapid heartbeat, rapid breathing and muscle stiffness, muscle pain and/or muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness or paralysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; long-term muscle disorder, usually observed when Esmeron and corticosteroids (anti-inflammatory drugs) are used in the Intensive Care Unit at the same time, in critically ill patients (steroid myopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; sudden fluid accumulation in the skin and mucous membranes (such as the throat or tongue), difficulty breathing and/or itching and rash, often as an allergic reaction (angioneurotic oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fluid accumulation (oedema) in the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; respiratory problems due to the anaesthesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash, sometimes with intense itching and formation of wheals (hives or urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; excessive blushing (&lsquo;flushing&rsquo;).</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>You can also report side effects directly via (The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA). By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Esmeron is stored in the hospital. Store in the refrigerator at 2-8&deg;C. The product can be stored outside the refrigerator at a temperature of up to 30&deg;C for a maximum of 3&nbsp;months. The product may be placed in and out the refrigerator at any point(s) during the 36&nbsp;month shelf life, but the total storage time outside the refrigerator must not exceed 3&nbsp;months. The storage period may not exceed the labeled shelf life.</p><p>&nbsp;</p><p>The hospital will keep Esmeron according to the correct storage conditions, and will ensure that it&#39;s in its expiry date</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is rocuronium bromide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium acetate, sodium chloride, acetic acid and water for injection. Each millilitre (ml) of Esmeron contains 1.72 mg of sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Esmeron is a colourless to slightly yellow/brown solution for injection or infusion, containing 10 mg/ml rocuronium bromide. Esmeron is available in three presentations:
•	2.5 ml injection vials with 25 mg of rocuronium bromide (10 vials per pack),
•	5 ml injection vials with 50 mg of rocuronium bromide (10 vials per pack),
•	10 ml injection vials with 100 mg rocuronium bromide (10 vials per pack).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder</u>:</p><p>N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands.</p><p>&nbsp;</p><p><u>Manufacturers</u>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands.</p><p>&nbsp;</p><p>For information or correspondence, please contact:</p><p>Merck Sharp &amp; Dohme BV, Waarderweg 39, 2031 BN Haarlem Tel. 0800 9999000, medicalinfo.nl@merck.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in November 2021.

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي إزميرون إلى أحد مجموعات الأدوية التي تُسمى مُرخيات العضلات.</p><p dir="RTL">تُستخدم مرخيات العضلات أثناء العمليات الجراحية كجزء من التخدير العام، إذ ينبغي أن تكون عضلاتك مسترخية تمامًا أثناء خضوعك لأي عملية جراحية، ومن شأن ذلك أن يُسهّل للجرّاح أداء العمليّة.</p><p dir="RTL">ترسل أعصابك عادة رسائل إلى عضلاتك تسمى نبضات. ويعمل إزميرون من خلال منع إرسال هذه النبضات وبالتالي يؤدي إلى استرخاء عضلاتك. ولأن عضلات التنفس لديك تسترخي أيضًا، ستحتاج إلى مساعدة على التنفس (التنفّس الاصطناعي) أثناء وبعد العملية حتى تتمكن من التنفس بمفردك.</p><p dir="RTL">سيقوم طبيب التخدير بالتحقق من تأثير مُرخي العضلات عليك باستمرار أثناء العملية، وسيعطيك المزيد إذا لزم الأمر. وعند الانتهاء من الجراحة، يُسمح لتأثير الدواء بالتلاشي وستبدأ في التنفس بنفسك. قد يلجأ طبيب التخدير أحيانًا إلى إعطائك دواء آخر للمساعدة في تسريع هذا الأمر.</p><p dir="RTL">يمكن استخدام إزميرون أيضًا في وحدات العناية المركزة للحفاظ على استرخاء عضلاتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ينبغي ألا تتلقّى </strong><strong>إزميرون</strong><strong>:</strong></p><p dir="RTL">&bull; &nbsp;<strong>إذا كنت تعاني من حساسية</strong> (فرط الحساسية) نحو روكيورونيوم و أيونات برومايد أو أي من المكونات الأخرى لهذا الدواء (المذكورة في البند 6).</p><p dir="RTL"><strong>&szlig;</strong><strong> </strong><strong>أخبر طبيب التخدير إذا كان هذا ينطبق عليك</strong><strong>.</strong></p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيب التخدير قبل أن تتلقى هذا الدواء:</p><p dir="RTL">&bull; إذا كان لديك حساسية نحو<strong> مرخيات العضلات</strong></p><p dir="RTL">&bull; إذا كنت تعاني من<strong> أمراض الكلى أو القلب أو الكبد أو المرارة</strong></p><p dir="RTL"><strong>&bull; </strong>إذا سبق وعانيت من أمراض تؤثر على<strong> الأعصاب والعضلات</strong></p><p dir="RTL"><strong>&bull; </strong>إذا كان لديك<strong> احتباس السوائل </strong>(وذمة).</p><p dir="RTL"><strong>-&gt; أخبر طبيب التخدير الخاص بك إذا كان أي مما ذُكر ينطبق عليك.</strong></p><p dir="RTL">&bull; إذا كان لديك تاريخ من الإصابة بارتفاع الحرارة الخبيث (حمى مفاجئة مع تسارع ضربات القلب، والتنفس السريع والتيبّس، والألم و/أو ضعف العضلات)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد تؤثر بعض الحالات الصحيّة على فعالية </strong><strong>إزميرون</strong> <strong>- على سبيل المثال:</strong></p><p dir="RTL">&bull; انخفاض مستويات الكالسيوم في الدم</p><p dir="RTL">&bull; انخفاض مستويات البوتاسيوم في الدم</p><p dir="RTL">&bull; ارتفاع مستويات المغنيسيوم في الدم</p><p dir="RTL">&bull; انخفاض مستويات البروتين في الدم</p><p dir="RTL">&bull; ارتفاع مستوى ثاني أكسيد الكربون في الدم</p><p dir="RTL">&bull; فقدان الكثير من سوائل الجسم، على سبيل المثال عن طريق الإصابة بالمرض أو الإسهال أو التعرق</p><p dir="RTL">&bull; الإفراط في التنفس يؤدي إلى انخفاض مستوى ثاني أكسيد الكربون في الدم (القلاء)</p><p dir="RTL">&bull; اعتلال الصحة العام</p><p dir="RTL">&bull; الحروق</p><p dir="RTL">&bull; زيادة الوزن (السمنة)</p><p dir="RTL">&bull; انخفاض شديد في درجة حرارة الجسم (انخفاض درجة حرارة الجسم).</p><p dir="RTL">إذا كان لديك أي من هذه الحالات، فإن طبيب التخدير سيأخذها بعين الاعتبار عند تحديد الجرعة الصحيحة لك من إزميرون.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال و كبار السن </strong></p><p dir="RTL">يمكن استخدام إزميرون لدى الأطفال (حديثي الولادة والمراهقين) وكبار السن ولكن يجب على طبيب التخدير تقييم تاريخك الطبي أولاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و إزميرون </strong></p><p dir="RTL">-&gt; أخبر طبيب التخدير الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى. وهذا يشمل الأدوية أو المنتجات العشبية التي حصلت عليها دون وصفة طبية. قد يؤثر إزميرون على أدوية أخرى أو قد يتأثر هو بها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية التي تزيد من تأثير إزميرون:</strong></p><p dir="RTL"><strong>&bull; </strong>بعض<strong> المضادات الحيوية</strong></p><p dir="RTL"><strong>&bull; </strong>بعض الأدوية التي تُستخدم لعلاج<strong> أمراض القلب </strong>أو<strong> ارتفاع ضغط الدم </strong>(أقراص الماء، حاصرات قنوات الكالسيوم، حاصرات بيتا والكيينيدين)</p><p dir="RTL"><strong>&bull; </strong>بعض الأدوية<strong> المضادة للالتهابات </strong>(الكورتيكوستيرويدات)</p><p dir="RTL"><strong>&bull; </strong>الأدوية التي تستخدم<strong> لعلاج مرض الهوس الاكتئابي </strong>(اضطراب المزاج ثنائي القطب)</p><p dir="RTL"><strong>&bull; أملاح المغنيسيوم</strong></p><p dir="RTL"><strong>&bull; </strong>بعض الأدوية المستخدمة لعلاج<strong> الملاريا.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية التي تقلل من تأثير إزميرون: </strong></p><p dir="RTL"><strong>&bull; </strong>بعض الأدوية التي تستخدم لعلاج<strong> الصرع&nbsp;</strong></p><p dir="RTL"><strong>&bull; كلوريد الكالسيوم وكلوريد البوتاسيوم</strong></p><p dir="RTL"><strong>&bull; </strong>بعض<strong> مثبطات أنزيم البروتياز </strong>مثل غابيكسيت ويوليناستاتين.</p><p dir="RTL">بالإضافة إلى ذلك، قد يتم إعطاؤك أدوية أخرى قبل أو أثناء الجراحة والتي يمكن أن تغير من تأثير إزميرون. وتشمل هذه بعض أدوية التخدير، مرخيات العضلات الأخرى، الأدوية مثل الفينيتوين والأدوية التي تعاكس تأثير إزميرون. كما قد يُسرّع إزميرون من عمل بعض أدوية التخدير. وسيأخذ طبيب التخدير هذا في الاعتبار عند تحديد الجرعة المناسبة لك من إزميرون.<br /><br /><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>-&gt; أخبري طبيب التخدير الخاص بكِ إذا كنتِ حامل أو تعتقدين أنك قد تكونين حامل أو إذا كنت مُرضع. </strong></p><p dir="RTL">بالرغم من ذلك، قد يقوم طبيب التخدير بإعطائك إزميرون. ولكنك تحتاجين إلى مناقشته أولاً. إذا كنت حامل أو مُرضع، تعتقدين أنك قد تكونين حامل أو تخططين لإنجاب طفل، استشيري طبيب التخدير أو أي طبيب آخر قبل تلقيك لهذا الدواء. يمكن إعطاؤك إزميرون إذا كنت ستخضعين لعملية قيصرية.</p><p dir="RTL">يجب إيقاف الرضاعة الطبيعية لمدة 6 ساعات بعد استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تجنب القيادة واستخدام الآلات إلى أن يتم إعلامك بأن ذلك آمن لك من قبل الطبيب. قد تشعر بالتعب أو الضعف أو الدوار لبعض الوقت بعد تلقيك إزميرون لأنه يُعطى كجزء من التخدير العام. سيرشدك أخصائي التخدير حول المدة التي من المرجح أن يستمر فيها تأثير هذا الدواء عليك.</p><p>Arabic translation.&nbsp;</p><p dir="RTL"><strong>إزميرون يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 مليمول صوديوم 23 ملغ لكل فيال ، أي &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة:</p><p dir="RTL">سيصف لك أخصائي التخدير الخاص بك جرعة إسميرون التي تحتاجها بناءً على:</p><p dir="RTL">&bull; نوع دواء التخدير</p><p dir="RTL">&bull; المدة الزمنية المتوقعة للعملية</p><p dir="RTL">&bull; الأدوية الأخرى التي تتناولها</p><p dir="RTL">&bull; حالتك الصحية.</p><p dir="RTL">الجرعة المعتادة من إزميرون هي 0,6 مجم لكل كيلوجرام من وزن الجسم ويستمر التأثير من 30-40 دقيقة.</p><p dir="RTL"><strong>كيف يتم إعطاء إزميرون</strong></p><p dir="RTL">سيتم إعطاؤك إزميرون من قبل طبيب التخدير. يتم إعطاء إزميرون عن طريق الحقن الوريدي (داخل الوريد)، إما كحقن منفرد أو بالتنقيط المستمر (بالتنقيط).</p><p dir="RTL"><strong>إذا تم إعطاؤك من </strong><strong>إزميرون</strong> <strong>أكثر مما تحتاجه</strong></p><p dir="RTL">من غير المرجح أن يتم إعطاؤك الكثير من إزميرون لأنك ستكون تحت إشراف طبيب التخدير الذي سيراقب حالتك بعناية. ومع ذلك، إذا حدث ذلك، فإن طبيب التخدير سيبقيك تحت تأثير التنفس الاصطناعي (على جهاز التنفس الاصطناعي) حتى تتمكّن من التنفس بنفسك. سوف تبقى نائما أثناء ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، مع أنها لا تحدث لدى الجميع. إذا حدثت هذه الأعراض الجانبية أثناء خضوعك للتخدير، فستتم ملاحظتها وعلاجها من قبل طبيب التخدير.</p><p dir="RTL"><strong>أعراض جانبية غير شائعة</strong></p><p dir="RTL">(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&bull; قد يكون الدواء فعّالاً جدًا، أو غير فعال بما فيه الكفاية</p><p dir="RTL">&bull; قد يعمل الدواء لفترة أطول من المتوقع</p><p dir="RTL">&bull; انخفاض ضغط الدم</p><p dir="RTL">&bull; زيادة في معدل ضربات القلب</p><p dir="RTL">&bull; ألم بالقرب من موقع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة جدا</strong></p><p dir="RTL">(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص)</p><p dir="RTL">&bull; تفاعلات تحسسية (فرط الحساسية) (مثل صعوبة في التنفس، وانهيار الدورة الدموية والصدمة)</p><p dir="RTL">&bull; صفير أثناء التنفس</p><p dir="RTL">&bull; ضعف العضلات</p><p dir="RTL">&bull; تورم أو طفح جلدي أو احمرار في الجلد.</p><p>Arabic translation.&nbsp;</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروف</strong> (لا يمكن تقدير التكرار من البيانات المتاحة )</p><p dir="RTL">تشنج الأوعية الدموية التاجية التحسسية الشديدة (متلازمة كونيس) مما يؤدي إلى ألم في الصدر (الذبحة الصدرية) &nbsp;أو نوبة قلبية (احتشاء عضلة القلب).</p><p dir="RTL"><strong>إذا تفاقم أيّ من الأعراض الجانبية </strong></p><p dir="RTL">أو إذا لاحظت ظهور أي أعراض جانبية غير مدرجة في هذه النشرة:</p><p dir="RTL"><strong>-&gt; أخبر طبيب التخدير الخاص بك أو أي طبيب آخر.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن أيّ أعراض جانبية </strong></p><p dir="RTL">في حال تعرّضت لأي أعراض جانبيّة ، تحدّث إلى الطبيب التخدير أو طبيبك المعالج. يشمل ذلك أي أعراض جانبيّة محتملة غير مدرجة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء السعودية&quot; المذكور في بند &quot;للإبلاغ عن الأعراض الجانبية&quot;. من خلال إبلاغك عن الأعراض الجانبية ، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ إزميرون في المستشفى . يُحفظ في الثلاجة في درجة حرارة 2-8 درجة مئوية. يمكن حفظ المنتج خارج الثلاجة عند درجة حرارة تصل إلى 30 درجة مئوية لمدة أقصاها 3 أشه . يمكن وضع المنتج داخل وخارج الثلاجة في أي وقت خلال فترة الصلاحية 36 شهرا، ولكن يجب أن لا يتجاوز إجمالي وقت التخزين خارج الثلاجة 3 أشهر. &nbsp;يجب أن &nbsp;لا تتجاوز فترة التخزين مدة الصلاحية.</p><p dir="RTL">سيتم حفظ إزميرون في المستشفى وفقًا لظروف التخزين الصحيحة، مع ضمان استخدامه أثناء مدة صلاحيته.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة لإزميرون هي روكيورونيوم برومايد 10 ملغم/مل.</p><p dir="RTL">المكونات الأخرى هي أسيتات الصوديوم (E262)، وكلوريد الصوديوم، وحامض الخليك (E260) والماء المُخصّص للحقن. يحتوي كل مليلتر (مل) من إزميرون على 1,72 مجم من الصوديوم. وهو خالٍ من أي مواد حافظة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لإزميرون ووصفه وحجم عبوته </strong></p><p dir="RTL">إزميرون هو محلول للحقن عديم اللون أو مائل إلى اللون الأصفر/البني قليلاً. وهو متوفر في فيال تحتوي على 25 ملغم (10 فيال في كل علبة)، و 50 ملغم (10 فيال في كل علبة) أو 100 ملغم (10 فيال في كل علبة) من روكيورونيوم برومايد .</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق والشركة الصانعة : </strong></p><p dir="RTL">ميرك شارب ودوهم بي في، واردرويغ &nbsp;39، 2021 بي إن، هارلم، هولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت آخر مراجعة لهذه النشرة بتاريخ نوفمبر 2021
للإبلاغ عن الأعراض الجانبية :
•	المملكة العربية السعودية :
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الإتصال بالمؤسسات و الهيئات الوطنية في كل دولة.

(ان هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلي هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال
مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
     تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء المملكة العربية السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esmeron 10 mg/ml, solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml Esmeron contains 10 mg rocuronium bromide. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. pH 3.8 – 4.2
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esmeron is indicated in adult and pediatric patients (from term neonates to adolescents [0 to 18 years]) as an adjunct to general anesthesia to facilitate tracheal intubation during routine induction and to provide skeletal muscle relaxation during surgery. In adults, Esmeron is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjuvant in the Intensive Care Unit (ICU) to facilitate tracheal intubation and mechanical ventilation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like other neuromuscular blocking agents, Esmeron should only be administered by, or under the supervision of, an experienced physician who is familiar with the action and use of these agents.</p><p>&nbsp;</p><p>As with other neuromuscular blocking agents, the dosage of Esmeron should be individualized for each patient. The method of anesthesia and the expected duration of surgery<em>, </em>the method of sedation and the expected duration of mechanical ventilation, possible interaction with other drugs that are administered concomitantly<em>,</em><em> </em>and the condition of the patient should be taken into account when determining the dose.</p><p>&nbsp;</p><p>The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery of neuromuscular function.</p><p>&nbsp;</p><p>Inhalational anesthetics potentiate the neuromuscular blocking effects of Esmeron. This potentiation only becomes clinically relevant during the course of the anesthesia, when the inhalational anesthetics have reached the tissue concentrations required for this interaction. Consequently, during lengthy procedures (lasting for longer than 1 hour) under inhalational anesthesia, lower maintenance doses of Esmeron should be administered at less frequent intervals or the infusion rates should be reduced (see section 4.5).</p><p>&nbsp;</p><p>In adults, the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to lengthy surgical procedures and for use in the ICU.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Surgical procedures</p><p><strong>&nbsp;</strong></p><p><u>Tracheal intubation</u></p><p>The standard intubating dose during routine anesthesia is 0.6 mg.kg-1&nbsp;rocuronium bromide, after which adequate intubation conditions are established within 60 seconds in nearly all patients. A dose of 1.0 mg.kg-1&nbsp;rocuronium bromide is recommended for facilitating tracheal intubation during rapid sequence induction of anesthesia, after which adequate intubation conditions are also established within 60 seconds in nearly all patients. If a dose of</p><p>0.6 mg.kg-1&nbsp;rocuronium bromide is used for rapid sequence induction of anesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide.</p><p>&nbsp;</p><p><u>Cesarean section</u></p><p>Doses of 0.6 mg.kg-1&nbsp;rocuronium bromide do not affect the Apgar score, fetal muscle tone or cardiorespiratory adaptation. From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs, which does not lead to clinical adverse effects in the newborn.</p><p>&nbsp;</p><p>Doses of 1.0 mg.kg-1&nbsp;have been investigated during rapid sequence induction of anesthesia, but not in patients undergoing Cesarean section.</p><p>&nbsp;</p><p><u>Higher doses</u></p><p>Should there be a reason for selecting a higher dose: initial doses up to 2 mg.kg-1&nbsp;rocuronium bromide have been administered to patients without adverse cardiovascular effects being noted. Use of a higher dose decreases the onset time and increases the duration of action (see section 5.1).</p><p>&nbsp;</p><p><u>Maintenance dose</u></p><p>The recommended maintenance dose is 0.15 mg.kg-1&nbsp;rocuronium bromide; in the case of prolonged inhalational anesthesia<em>,</em><em> </em>this should be reduced to 0.075-0.1 mg.kg-1&nbsp;rocuronium bromide. The maintenance doses should best be given when twitch height has recovered to 25% of control twitch height, or when 2 to 3 responses to TOF-stimulation (train of four) are present.</p><p>&nbsp;</p><p><u>Continuous infusion</u></p><p>If rocuronium bromide is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg.kg-1&nbsp;rocuronium bromide. When neuromuscular function starts to recover, administration by continuous infusion can be started. The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to TOF stimulation. In adults under intravenous anesthesia, this corresponds to an infusion rate of 0.3-0.6 mg.kg-1.h-1, and under inhalational anesthesia to an infusion rate of 0.3-0.4 mg.kg-1.h-1. Continuous monitoring of neuromuscular block is recommended, since &nbsp;the required dosage varies from patient to patient and depends on the anesthetic method used.</p><p>&nbsp;</p><p><u>Pediatric patients</u></p><p>For neonates (0-27 days), infants (28 days-2 months), toddlers (3-23 months), children (2-11 years) and adolescents (12-17 years), the recommended intubation dose during routine anesthesia and maintenance dose are similar to those in adults.</p><p>However, the duration of action of the single intubating dose will be longer in neonates and infants than in children (see section 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>For continuous infusion in pediatric patients, the infusion rates, with the exception of children (2-11 years), are the same as for adults. For children aged 2-11 years, higher infusion rates might be necessary.</p><p>&nbsp;</p><p>Thus, for children (2-11 years), the same initial dosage as for adults is recommended; this should then be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to TOF-stimulation during the procedure.</p><p>&nbsp;</p><p>Experience with rocuronium bromide during rapid sequence induction in pediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitating tracheal intubation conditions during rapid sequence induction in pediatric patients.</p><p>&nbsp;</p><p><u>Geriatric patients and patients with hepatic and/or biliary tract disorders and/or renal failure</u> The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disorders and/or renal failure during routine anesthesia is 0.6 mg.kg-1&nbsp;rocuronium bromide. A dose of 0.6 mg.kg-1&nbsp;should be considered for rapid sequence induction of anesthesia in patients in whom a prolonged duration of action is expected. Regardless of the anesthetic technique used, the recommended maintenance dose for these patients is</p><p>0.075-0.1 mg.kg-1&nbsp;rocuronium bromide, and the recommended infusion rate is 0.3-0.4 mg.kg-1.h-1&nbsp;(see &#39;Continuous infusion&#39; and also section 4.4).</p><p>&nbsp;</p><p><u>Overweight and obese patients</u></p><p>When used in overweight or obese patients (defined as patients with a body weight of 30% or more above ideal body weight), doses should be reduced and calculated on the basis of ideal body weight.</p><p>&nbsp;</p><p>Use in Intensive Care</p><p><strong>&nbsp;</strong></p><p><u>Tracheal intubation</u></p><p>For tracheal intubation, the dose recommendations are the same as for surgical procedures.</p><p>&nbsp;</p><p><u>Maintenance dose</u></p><p>The use of an initial loading dose of 0.6 mg.kg-1&nbsp;rocuronium bromide is recommended, followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1 to 2 twitches to TOF-stimulation. Dosage should always be titrated to effect in the individual patient. The recommended initial infusion rate for the maintenance of a neuromuscular block of 80 - 90% (1 to 2 twitches to TOF-stimulation) in adult patients is</p><p>0.3 - 0.6 mg.kg-1.h-1&nbsp;during the first hours of administration. The infusion rate should be decreased during the following 6 - 12 hours, according to the individual response. Thereafter,</p><p>dose requirements remain relatively constant.</p><p>&nbsp;</p><p>A high variability in infusion rates was seen in clinical studies. The mean infusion rate ranged from 0.2-0.5 mg.kg-1.h-1&nbsp;depending on the nature and extent of organ failure, concomitant medication and the condition of the individual patient. To provide optimal individual patient control, monitoring of neuromuscular transmission is strongly recommended. Administration for up to 7 days has been investigated.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Esmeron is not recommended for the facilitation of mechanical ventilation in pediatric and geriatric patients due to a lack of data on safety and efficacy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Administration</p><p><strong>&nbsp;</strong></p><p>Esmeron is administered intravenously either as a bolus injection or as a continuous infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity  to  rocuronium  or  the  bromide  ion  or  to  any  of  the  excipients  listed  in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Esmeron causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this drug until adequate spontaneous respiration is restored. As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a rapid sequence induction technique.</p><p>&nbsp;</p><p>As with other neuromuscular blocking agents, residual neuromuscular blockade has been reported for Esmeron. In order to prevent complications resulting from residual neuromuscular blockade, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block. Other factors which could cause residual neuromuscular blockade after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. &nbsp;If not used as part of standard clinical practice, the use of a reversal agent (such as sugammadex or acetylcholinesterase inhibitors) should be considered, especially in those cases where residual neuromuscular blockade is more likely to occur.</p><p>&nbsp;</p><p>High rates of cross-sensitivity between neuromuscular blocking agents have been reported. Therefore, where possible, before administering Esmeron, hypersensitivity to other neuromuscular blocking agents should be excluded. Esmeron should only be used when absolutely essential in susceptible patients. Patients who experience a hypersensitivity reaction under general anaesthesia should be tested subsequently for hypersensitivity to other neuromuscular blockers.</p><p>&nbsp;</p><p>Rocuronium may increase the heart rate.</p><p>In general, following long-term use of neuromuscular blocking agents in the ICU, prolonged paralysis and/or skeletal muscle weakness has been noted. &nbsp;In order to help preclude possible prolongation of neuromuscular block and/or overdosage it is strongly recommended that neuromuscular transmission is monitored throughout the use of neuromuscular blocking agents.&nbsp; In addition, patients should receive adequate analgesia and sedation. &nbsp;&nbsp;Furthermore, neuromuscular blocking agents should be titrated to effect in the individual patients by or under supervision of experienced clinicians who are familiar with their actions and with appropriate neuromuscular monitoring techniques.</p><p>&nbsp;</p><p>Myopathy after long-term administration of other non-depolarising neuromuscular blocking agents in the ICU in combination with corticosteroid therapy has been reported regularly. Therefore, for patients receiving both neuromuscular blocking agents and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible.</p><p>&nbsp;</p><p>If suxamethonium is used for intubation, the administration of Esmeron should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.</p><p>&nbsp;</p><p>Because rocuronium bromide is always used with other drugs and because of the risk of malignant hyperthermia during anesthesia, even in the absence of known triggering factors, physicians should be aware of the early symptoms, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of anesthesia. Animal studies have shown that rocuronium bromide is not a triggering factor for malignant hyperthermia. Rare cases of malignant hyperthermia with ESMERON have been observed thru post-marketing surveillance; however, the causal association has not been proven.</p><p>&nbsp;</p><p><strong>The following conditions may influence the pharmacokinetics and/or pharmacodynamics of Esmeron:</strong></p><p><u>Hepatic and/or biliary tract disease and renal failure</u></p><p>Because rocuronium is excreted in urine and bile, it should be used with caution in patients with clinically significant hepatic and/or biliary diseases and/or renal failure. In these patient groups prolongation of action has been observed with doses of 0.6 mg/kg rocuronium bromide.</p><p>&nbsp;</p><p><u>Prolonged circulation time</u></p><p>Conditions associated with prolonged circulation time such as cardiovascular disease, old age and oedematous state resulting in an increased volume of distribution, may contribute to a slower onset of action. &nbsp;The duration of action may also be prolonged due to a reduced plasma clearance.</p><p>&nbsp;</p><p><u>Neuromuscular disease</u></p><p>Like other neuromuscular blocking agents, Esmeron should be used with extreme caution in patients with a neuromuscular disease or after poliomyelitis since the response to neuromuscular blocking agents may be considerably altered in these cases. &nbsp;The magnitude and direction of this alteration may vary widely. &nbsp;In patients with myasthenia gravis or with the myasthenic (Eaton-Lambert) syndrome, small doses of Esmeron may have profound effects and Esmeron should be titrated to the response.</p><p>&nbsp;</p><p><u>Hypothermia</u></p><p>In surgery under hypothermic conditions, the neuromuscular blocking effect of Esmeron is increased and the duration prolonged.</p><p>&nbsp;</p><p><u>Obesity</u></p><p>Like other neuromuscular blocking agents, Esmeron may exhibit a prolonged duration and a prolonged spontaneous recovery in obese patients when the administered doses are calculated on actual body weight.</p><p><em>&nbsp;</em></p><p><u>&nbsp;</u></p><p><u>Burns</u></p><p>Patients with burns are known to develop resistance to non-depolarising neuromuscular blocking agents. &nbsp;It is recommended that the dose is titrated to response.</p><p>&nbsp;</p><p><u>Conditions which may increase the effects of Esmeron</u></p><p>Hypokalaemia (e.g. after severe vomiting, diarrhoea and diuretic therapy), hypermagnesaemia, hypocalcaemia (after massive transfusions), hypoproteinaemia, dehydration, acidosis, hypercapnia, cachexia.</p><p>&nbsp;</p><p>Severe electrolyte disturbances, altered blood pH or dehydration should therefore be corrected when possible.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following drugs have been shown to influence the magnitude and/or duration of action of non-depolarizing neuromuscular blocking agents.</p><p>&nbsp;</p><p><u>Increased effect</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halogenated volatile anesthetics potentiate the neuromuscular block of rocuronium bromide. The effect only becomes apparent with maintenance dosing (see section 4.2). Reversal of the block with anticholinesterase inhibitors could also be inhibited</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after intubation with suxamethonium (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term use of corticosteroids and rocuronium bromide in the ICU may result in a prolonged duration of neuromuscular block or myopathy (see sections 4.4 and 4.8)</p><p>Other drugs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics: aminoglycoside and polypeptide antibiotics, lincosamide and acylamino- penicillin antibiotics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diuretics, quinidine and its isomer quinine, magnesium salts, calcium channel blocking agents, lithium salts, local anesthetics (lidocaine i.v, bupivacaine epidural) and acute administration of phenytoin or &szlig;-blocking agents.</p><p>Recurarization has been reported after post-operative administration of: aminoglycoside, lincosamide, polypeptide and acylamino-penicillin antibiotics, quinidine, quinine and magnesium salts (see section 4.4).</p><p>&nbsp;</p><p><u>Decreased effect</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prior chronic administration of corticosteroids, phenytoin or carbamazepine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protease inhibitors (gabexate, ulinastatin).</p><p>&nbsp;</p><p><u>Variable effect</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; administration of other non-depolarizing neuromuscular blocking agents in combination with rocuronium bromide may produce attenuation or potentiation of the neuromuscular block, depending on the order of administration and the neuromuscular blocking agent used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suxamethonium given after the administration of rocuronium bromide may produce potentiation or attenuation of the neuromuscular blocking effect.</p><p>&nbsp;</p><p><u>Effect of rocuronium bromide on other drugs</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rocuronium bromide combined with lidocaine may result in a quicker onset of action of lidocaine.</p><p>&nbsp;</p><p><u>Pediatric patients</u></p><p>No formal interaction studies have been performed. The above-mentioned interactions for adults and their special warnings and precautions for use (see section 4.4) should also be taken into account for pediatric patients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no clinical data on the use of rocuronium bromide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see section 5.3). Caution should be exercised when administering rocuronium bromide to pregnant women.</p><p>&nbsp;</p><p><u>Cesarean section</u></p><p>In patients undergoing Cesarean section, rocuronium bromide can be used as part of a rapid sequence induction technique, provided no intubation difficulties are anticipated and a sufficient dose of anesthetic agent is administered or suxamethonium is used during intubation. Rocuronium bromide, administered in doses of 0.6 mg.kg-1, has been shown to be safe for use during Cesarean section. Rocuronium bromide does not affect Apgar score, fetal muscle tone or cardiorespiratory adaptation. From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs, which does not lead to the observation of clinical adverse effects in the newborn.</p><p>&nbsp;</p><p>N.B.:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; doses of 1.0 mg.kg-1&nbsp;have been investigated during rapid sequence induction of anesthesia, but not in Cesarean section patients. Therefore, only a dose of 0.6 mg.kg-1&nbsp;is recommended in this patient group.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversal of neuromuscular block induced by neuromuscular blocking agents may be inhibited or unsatisfactory in patients receiving magnesium salts for toxemia of pregnancy because magnesium salts enhance neuromuscular blockade. Therefore, in these patients the dosage of rocuronium bromide should be reduced and be titrated to twitch response.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>It is unknown whether rocuronium bromide is excreted in breast milk. Other medicinal products of the same class demonstrate limited secretion in breast milk and low resorption by the infant. Insignificant levels of rocuronium bromide were found in the milk of lactating rats. Rocuronium bromide should only be given to women who are breastfeeding when the attending physician decides that the benefits outweigh the risks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Since rocuronium bromide is used as an adjunct to general anesthesia, the usual precautionary measures after a general anesthesia should be taken for ambulatory patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse drug reactions include injection site pain/reaction, changes in vital signs and prolonged neuromuscular block. The most frequently reported serious adverse drug reaction during post-marketing surveillance is &lsquo;anaphylactic and anaphylactoid reactions&rsquo; and associated symptoms. See also the explanations below the table.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:70.65pt;margin-top:-363.95pt;width:447.4pt;
 height:370.1pt;text-indent:0;z-index:251657728;
 mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA System organ class</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MedDRA preferred term</strong><strong>1</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon/rare2</p><p>(&lt;1/100, &gt;1/10,000)</p></td><td style="vertical-align:top"><p>Very rare2</p><p>(&lt;1/10,000)</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity Anaphylactic reaction Anaphylactoid reaction Anaphylactic shock Anaphylactoid shock</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flaccid paralysis</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Circulatory collapse and shock Flushing</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioneurotic edema Urticaria</p><p>Rash Erythematous rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscular weakness3</p><p>Steroid myopathy3</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Drug ineffective</p><p>Drug effect/ therapeutic response decreased Drug effect/ therapeutic response increased Injection site pain Injection site reaction</p></td><td style="vertical-align:top"><p>Face edema</p><p>Malignant hyperthermia</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Prolonged neuromuscular block</p><p>Delayed recovery from anesthesia</p></td><td style="vertical-align:top"><p>Airway complication of anesthesia</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>1 &nbsp;Frequencies are estimates derived from post-marketing surveillance reports and data from the general literature.</p><p>&nbsp;</p><p>2 &nbsp;Post-marketing surveillance data cannot give precise incidence figures. For that reason, the reporting frequency was divided over two rather than five categories.</p><p>3 &nbsp;After long-term use in the Intensive Care.</p><p>&nbsp;</p><p><u>Class effects</u></p><p><em>Anaphylactic</em><em> </em><em>reactions</em></p><p>Although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. Anaphylactic/anaphylactoid reactions include symptoms such as bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia and circulatory collapse/shock) and cutaneous changes (e.g. angioedema and urticaria). These reactions have been fatal in some cases. Due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions (see also section 4.4).</p><p>&nbsp;</p><p><em>Histamine</em><em> release and histaminoid reactions</em></p><p>Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematous reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under &#39;Anaphylactic reactions&#39; above) should always be taken into consideration when administering these drugs.</p><p>In clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3-0.9 mg.kg-1&nbsp;rocuronium bromide.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Prolonged</em><em> </em><em>neuromuscular</em><em> </em><em>block</em></p><p>The most frequent adverse reaction to neuromuscular blocking agents as a class consists of prolongation of the drug&rsquo;s pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnea.</p><p>&nbsp;</p><p><u>Myopathy</u></p><p>Myopathy has been reported after the use of various neuromuscular blocking agents in the ICU in combination with corticosteroids (see also sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Local injection site reactions</u></p><p>During rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental.</p><p>&nbsp;</p><p><u>Pediatric patients</u></p><p>A meta-analysis of 11 clinical studies in pediatric patients (n=704) with rocuronium bromide (up to 1 mg/kg) showed that tachycardia occurred as an adverse drug reaction with a frequency of 1.4%.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage and prolonged neuromuscular block, the patient should continue to receive ventilatory support and sedation. In this situation there are two options for the reversal of neuromuscular block:</p><p>(1)&nbsp; In adults, sugammadex can be used for reversal of intense (profound) and deep block. The dose of sugammadex to be administered depends on the level of neuromuscular block.</p><p>(2)&nbsp; An acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) or sugammadex can be used once spontaneous recovery starts and should be administered at the correct dose. When administration of an acetylcholinesterase inhibitor fails to reverse the neuromuscular effects of rocuronium bromide, ventilation must be continued until spontaneous breathing is restored. Repeated administration of an acetylcholinesterase inhibitor can be dangerous.</p><p>&nbsp;</p><p>In animal studies, severe depression of cardiovascular function, eventually leading to cardiac failure, did not occur until a cumulative dose of 750 x ED90&nbsp;(135 mg rocuronium bromide per kg body weight) was administered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group (ATC code)</u></p><p>Muscle relaxants, peripherally acting agents. ATC code: M03A C09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Esmeron (rocuronium bromide) is a fast-onset, non-depolarizing neuromuscular blocking agent which has all of the pharmacological properties characteristic of this class of drugs (curariform). It acts by competitive blockade of nicotinic cholinoceptors at the motor endplate. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The ED90&nbsp;(dose required to produce 90% depression of the twitch response of the thumb to stimulation of the ulnar nerve) during intravenous anesthesia is approximately 0.3 mg.kg-1&nbsp;rocuronium bromide. The ED95&nbsp;in neonates and infants is lower than in adults and children</p><p>(0.25, 0.35 and 0.40 mg.kg-1, respectively).</p><p>&nbsp;</p><p>The clinical duration of action (the time between administration and recovery to 25% of control twitch height) at a dose of 0.6 mg.kg-1&nbsp;rocuronium bromide is 30-40 minutes. The total duration of action (time until spontaneous recovery to 90% of control twitch height) is</p><p>50 minutes. The mean time of spontaneous recovery of twitch response from 25% to 75% after a bolus dose of 0.6 mg.kg-1&nbsp;rocuronium bromide is 14 minutes. With lower doses of</p><p>0.3-0.45 mg.kg-1&nbsp;rocuronium bromide (1-1.5 x ED90), onset of action is slower and duration of action is shorter. With a higher dose of 2 mg.kg-1, the duration of action is 110 minutes.</p><p>&nbsp;</p><p><u>Intubation during routine anesthesia</u></p><p>Within 60 seconds following intravenous administration of a dose of 0.6 mg.kg-1&nbsp;rocuronium bromide (2x ED90&nbsp;under intravenous anesthesia), adequate intubation conditions can be achieved in nearly all patients, of which in 80% intubation conditions are rated as excellent. General muscle paralysis adequate for any type of procedure is established within 2 minutes after administration of this dose. After administration of 0.45 mg.kg-1&nbsp;rocuronium bromide, acceptable intubation conditions are achieved after 90 seconds.</p><p>&nbsp;</p><p><u>Rapid sequence induction</u></p><p>During rapid sequence induction of anesthesia with propofol or fentanyl/thiopental, adequate intubation conditions are achieved within 60 seconds in 93% and 96% of the patients respectively, following a dose of 1.0 mg.kg-1&nbsp;rocuronium bromide. In these groups, in 70% of the cases the intubation conditions are rated as excellent. The clinical duration of action with this dose approaches 1 hour, after which the neuromuscular block can be safely reversed.</p><p>Following a dose of 0.6 mg.kg-1&nbsp;rocuronium bromide, adequate intubation conditions are achieved within 60 seconds in 81% and 75% of the patients during a rapid sequence</p><p>induction technique with propofol and fentanyl/thiopental, respectively.</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>Mean onset time in infants, toddlers and children at an intubation dose of 0.6 mg.kg-1&nbsp;is slightly shorter than in adults. Comparisons between the pediatric age groups showed that &nbsp;the mean onset time in neonates and adolescents (1.0 min.) is slightly longer than in infants, toddlers and children (0.4, 0.6 and 0.8 min., respectively). The duration of action and the time to recovery tend to be shorter in children compared to infants and adults.</p><p>Comparisons between the pediatric age groups demonstrated that the mean time to</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>reappearance of T3&nbsp;was prolonged in neonates and infants (56.7 and 60.7 min., respectively) in comparison with toddlers, children and adolescents (45.5, 37.6 and 42.9 min., respectively).</p><p>&nbsp;</p><p>Mean (SD) time to onset and clinical duration of action following an initial intubating dose* of 0.6 mg/kg rocuronium bromide during sevoflurane/nitrous oxide and isoflurane/nitrous oxide (maintenance) anesthesia (pediatric patients)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Time to maximum block** (min)</p></td><td style="vertical-align:top"><p>Time to reappearance of T3** (min)</p></td></tr><tr><td style="vertical-align:top"><p>Neonates (0-27 days) n=10</p></td><td style="vertical-align:top"><p>0.98 (0.62)</p></td><td style="vertical-align:top"><p>56.69 (37.04)</p><p>n=9</p></td></tr><tr><td style="vertical-align:top"><p>Infants (28 days-</p><p>2 months) n=11</p></td><td style="vertical-align:top"><p>0.44 (0.19) n=10</p></td><td style="vertical-align:top"><p>60.71 (16.52)</p></td></tr><tr><td style="vertical-align:top"><p>Toddlers (3-23 months) n=28</p></td><td style="vertical-align:top"><p>0.59 (0.27)</p></td><td style="vertical-align:top"><p>45.46 (12.94) n=27</p></td></tr><tr><td style="vertical-align:top"><p>Children (2-11 years) n=34</p></td><td style="vertical-align:top"><p>0.84 (0.29)</p></td><td style="vertical-align:top"><p>37.58 (11.82)</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (12-17 years) n=31</p></td><td style="vertical-align:top"><p>0.98 (0.38)</p></td><td style="vertical-align:top"><p>42.90 (15.83) n=30</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp; Dose of rocuronium bromide administered within 5 seconds.</p><p>** &nbsp;Calculated from the end of administration of the rocuronium bromide intubating dose.</p><p>&nbsp;</p><p><u>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</u> The duration of action of maintenance doses of 0.15 mg.kg-1&nbsp;rocuronium bromide might be somewhat longer under enflurane and isoflurane anesthesia in geriatric patients and in patients with hepatic disease and/or renal disease (approximately 20 minutes) than in patients without impairment of excretory organ functions under intravenous anesthesia (approximately 13 minutes) (see section 4.2). No accumulation of effect (progressive increase in duration of action) has been observed with repeated maintenance doses at the recommended level.</p><p>&nbsp;</p><p><u>ICU</u></p><p>Following prolonged continuous infusion in the ICU, the time to recovery of the TOF-ratio to</p><p>0.7 depends on the level of neuromuscular block at the end of the infusion. After continuous infusion for 20 hours or more, the median time between return of T2&nbsp;to TOF-stimulation and recovery of the TOF-ratio to 0.7 is approximately 1.5 (range 1-5) hours in patients without multiple organ failure and 4 (range 1-25) hours in patients with multiple organ failure.</p><p>&nbsp;</p><p><u>Cardiovascular surgery</u></p><p>In patients undergoing cardiovascular surgery, the most common cardiovascular changes during the onset of maximum block following 0.6-0.9 mg.kg-1&nbsp;rocuronium bromide are a slight and clinically insignificant increase in heart rate up to 9% and an increase in mean arterial blood pressure up to 16% from the control values.</p><p>&nbsp;</p><p><u>Reversal of muscle relaxation</u></p><p>The action of rocuronium bromide can be antagonized either by sugammadex or by acetylcholinesterase inhibitors (neostigmine, pyridostigmine or edrophonium). Sugammadex can be given for routine reversal (at 1-2 post-tetanic counts up to reappearance of T2) or for immediate reversal (3 minutes after rocuronium bromide administration).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Acetylcholinesterase inhibitors can be administered at reappearance of T2 or at the first signs of clinical recovery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intravenous administration of a single bolus dose of rocuronium bromide, the plasma concentration time course runs in three exponential phases. In adults, the mean elimination half-life is 73 (95% CI: 66-80) minutes, the (apparent) volume of distribution under steady-state conditions is 203 (193-214) ml.kg-1&nbsp;and plasma clearance is 3.7 (3.5-3.9) ml.kg-1.min-1.</p><p>&nbsp;</p><p>Rocuronium is excreted in urine and bile. Excretion in urine approaches 40% within 12-24 hours. After injection of a radiolabeled dose of rocuronium bromide, excretion of the radiolabel is on average 47% in urine and 43% in feces after 9 days. Approximately 50% is recovered as unchanged rocuronium.</p><p>&nbsp;</p><p><u>Pediatric patients</u></p><p>The pharmacokinetics of rocuronium bromide in pediatric patients (n=146) with ages ranging from 0 to 17 years were evaluated using a population analysis of the pooled pharmacokinetic datasets from two clinical trials in which anesthesia was induced with sevoflurane and maintained with isoflurane/nitrous oxide. All pharmacokinetic parameters were found to be linearly proportional to body weight, illustrated by a similar clearance (l.hr-1.kg-1). The volume of distribution (l.kg-1) and elimination half-life (h) decrease with age (years). The pharmacokinetic parameters of typical pediatric patients within each age group are summarized below:</p><p>&nbsp;</p><p>Estimated PK parameters (mean [SD]) of rocuronium bromide in typical pediatric patients during sevoflurane and nitrous oxide (induction) and isoflurane/nitrous oxide (maintenance anesthesia)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>PK parameters</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Patient age range</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Term newborn infants</p><p>(0-27 days)</p></td><td style="vertical-align:top"><p>Infants (28 days -</p><p>2 months)</p></td><td style="vertical-align:top"><p>Toddlers (3-23</p><p>months)</p></td><td style="vertical-align:top"><p>Children (2-11 years)</p></td><td style="vertical-align:top"><p>Adolescents (12-17 years)</p></td></tr><tr><td style="vertical-align:top"><p>Cl (l/kg/hr)</p></td><td style="vertical-align:top"><p>0.31 (0.07)</p></td><td style="vertical-align:top"><p>0.30 (0.08)</p></td><td style="vertical-align:top"><p>0.33 (0.10)</p></td><td style="vertical-align:top"><p>0.35 (0.09)</p></td><td style="vertical-align:top"><p>0.29 (0.14)</p></td></tr><tr><td style="vertical-align:top"><p>Volume of distribution (l/kg)</p></td><td style="vertical-align:top"><p>0.42 (0.06)</p></td><td style="vertical-align:top"><p>0.31 (0.03)</p></td><td style="vertical-align:top"><p>0.23 (0.03)</p></td><td style="vertical-align:top"><p>0.18 (0.02)</p></td><td style="vertical-align:top"><p>0.18 (0.01)</p></td></tr><tr><td style="vertical-align:top"><p>t&frac12;&beta; (hr)</p></td><td style="vertical-align:top"><p>1.1 (0.2)</p></td><td style="vertical-align:top"><p>0.9 (0.3)</p></td><td style="vertical-align:top"><p>0.8 (0.2)</p></td><td style="vertical-align:top"><p>0.7 (0.2)</p></td><td style="vertical-align:top"><p>0.8 (0.3)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Geriatric patients and patients with hepatic and/or biliary tract disorders and/or renal failure</u> In controlled studies the plasma clearance in geriatric patients and in patients with renal failure was reduced. In most studies, however, this did not reach the level of statistical significance. In patients with hepatic failure, the mean elimination half-life is prolonged by 30 minutes and the mean plasma clearance is reduced by 1 ml.kg-1.min-1&nbsp;(see section 4.2).</p><p>&nbsp;</p><p>I<u>ntensive</u><u> Care</u></p><p>When administered as a continuous infusion to facilitate mechanical ventilation for 20 hours or more, the mean elimination half-life and the mean (apparent) volume of distribution at steady state are increased. A large interindividual variability was found in controlled clinical studies, related to the nature and extent of (multiple) organ failure and individual patient characteristics. In patients with multiple organ failure, the mean (&plusmn; SD) elimination half-life is</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-1</p><p>21.5 (&plusmn; 3.3) hours, the (apparent) volume of distribution at steady state is 1.5 (&plusmn; 0.8) l.kg</p><p>and the plasma clearance is 2.1 (&plusmn; 0.8) ml.kg-1.min-1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in animal studies were observed only at exposures sufficiently in excess of the maximum human exposure, indicating little relevance to clinical use.</p><p>&nbsp;</p><p>There is no proper animal model to mimic the usually extremely complex clinical situation of the ICU patient. Therefore, the safety of Esmeron when used to facilitate mechanical ventilation in the ICU has primarily been assessed on the basis of the results obtained in clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esmeron contains the following excipients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium acetate (for pH adjustment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetic acid (for pH adjustment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibility has been documented for Esmeron when added to solutions containing the following drugs: amphotericin, amoxicillin, azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, hydrocortisone sodium succinate, insulin, methohexital, methylprednisolone, prednisolone sodium succinate, thiopental, trimethoprim and vancomycin. Esmeron is also incompatible with Intralipid.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products other than those mentioned in section 6.6.</p><p>&nbsp;</p><p>If Esmeron is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed (e.g. with 0.9% NaCl) between administration of Esmeron and drugs for which incompatibility with Esmeron has been demonstrated or for which compatibility with Esmeron has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

Esmeron does not contain a preservative; the solution should be used immediately after opening the vial.

The chemical and physical in-use stability of the diluted product (see section 6.6) has been demonstrated for 72 hours at 30˚C. From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage times and
 


conditions prior to use are the responsibility of the user/administrator and would normally not be longer than 24 hours at 2 to 8˚C, unless the dilution method rules out microbiological contamination.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Storage in the Refrigerator</u></p><p>Esmeron should be stored at 2&deg;-8&deg;C in the dark and used within the expiry date given on the pack.</p><p><u>Storage out of the refrigerator</u></p><p>Esmeron can be stored outside the refrigerator at a temperature of up to 30&deg;C for a maximum of 3&nbsp;months. The product may be placed in and out the refrigerator at any point(s) during the 36&nbsp;month shelf life, but the total storage time outside the refrigerator must not exceed 3&nbsp;months. The storage period must not exceed the labelled shelf life.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass vial, rubber stopper and aluminum crimp cap with plastic cap. The rubber stopper of the vial does not contain latex.</p><p>&nbsp;</p><p>There are 3 presentations of Esmeron:</p><p>-&nbsp; Packaging of 10 vials of 2.5 ml each containing 25 mg rocuronium bromide.</p><p>-&nbsp; Packaging of 10 vials of 5 ml each containing 50 mg rocuronium bromide.</p><p>-&nbsp; Packaging of 10 vials of 10 ml each containing 100 mg rocuronium bromide. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compatibility studies have been performed with the following infusion fluids. In nominal concentrations of 0.5 mg/ml and 2.0 mg/ml, Esmeron has been shown to be compatible with: 0.9% NaCl, 5% dextrose, 5% dextrose in 0.9% NaCl, sterile water for injections, lactated Ringers and Haemaccel. Administration should be started immediately after mixing, and should be completed within 24 hours. Any unused solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                31 December 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>